Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma

results of the EORTC 18961 randomized phase III trial

Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, Jeremy Marsden, Mario Santinami, Philippa Corrie, Steinar Aamdal, Paolo A Ascierto, Poulam M Patel, Wim H Kruit, Lars Bastholt, Lorenzo Borgognoni, Maria Grazia Bernengo, Neville Davidson, Larissa Polders, Michel Praet, Alan Spatz

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.
OriginalsprogEngelsk
TidsskriftJournal of Clinical Oncology
Vol/bind31
Udgave nummer30
Sider (fra-til)3831-3837
ISSN0732-183X
DOI
StatusUdgivet - 2013

Fingeraftryk

G(M2) Ganglioside
Melanoma
Observation
Neoplasms
QS 21

Citer dette

Eggermont, Alexander M M ; Suciu, Stefan ; Rutkowski, Piotr ; Marsden, Jeremy ; Santinami, Mario ; Corrie, Philippa ; Aamdal, Steinar ; Ascierto, Paolo A ; Patel, Poulam M ; Kruit, Wim H ; Bastholt, Lars ; Borgognoni, Lorenzo ; Bernengo, Maria Grazia ; Davidson, Neville ; Polders, Larissa ; Praet, Michel ; Spatz, Alan. / Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma : results of the EORTC 18961 randomized phase III trial. I: Journal of Clinical Oncology. 2013 ; Bind 31, Nr. 30. s. 3831-3837.
@article{e31cfa9a3a1148b7ba9f7d64f50b8df4,
title = "Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial",
abstract = "The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.",
keywords = "Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Cancer Vaccines, Disease-Free Survival, Female, G(M2) Ganglioside, Hemocyanin, Humans, Kaplan-Meier Estimate, Lymph Nodes, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Neoplasm Staging, Saponins, Skin Neoplasms, Watchful Waiting",
author = "Eggermont, {Alexander M M} and Stefan Suciu and Piotr Rutkowski and Jeremy Marsden and Mario Santinami and Philippa Corrie and Steinar Aamdal and Ascierto, {Paolo A} and Patel, {Poulam M} and Kruit, {Wim H} and Lars Bastholt and Lorenzo Borgognoni and Bernengo, {Maria Grazia} and Neville Davidson and Larissa Polders and Michel Praet and Alan Spatz",
year = "2013",
doi = "10.1200/JCO.2012.47.9303",
language = "English",
volume = "31",
pages = "3831--3837",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

Eggermont, AMM, Suciu, S, Rutkowski, P, Marsden, J, Santinami, M, Corrie, P, Aamdal, S, Ascierto, PA, Patel, PM, Kruit, WH, Bastholt, L, Borgognoni, L, Bernengo, MG, Davidson, N, Polders, L, Praet, M & Spatz, A 2013, 'Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial', Journal of Clinical Oncology, bind 31, nr. 30, s. 3831-3837. https://doi.org/10.1200/JCO.2012.47.9303

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma : results of the EORTC 18961 randomized phase III trial. / Eggermont, Alexander M M; Suciu, Stefan; Rutkowski, Piotr; Marsden, Jeremy; Santinami, Mario; Corrie, Philippa; Aamdal, Steinar; Ascierto, Paolo A; Patel, Poulam M; Kruit, Wim H; Bastholt, Lars; Borgognoni, Lorenzo; Bernengo, Maria Grazia; Davidson, Neville; Polders, Larissa; Praet, Michel; Spatz, Alan.

I: Journal of Clinical Oncology, Bind 31, Nr. 30, 2013, s. 3831-3837.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma

T2 - results of the EORTC 18961 randomized phase III trial

AU - Eggermont, Alexander M M

AU - Suciu, Stefan

AU - Rutkowski, Piotr

AU - Marsden, Jeremy

AU - Santinami, Mario

AU - Corrie, Philippa

AU - Aamdal, Steinar

AU - Ascierto, Paolo A

AU - Patel, Poulam M

AU - Kruit, Wim H

AU - Bastholt, Lars

AU - Borgognoni, Lorenzo

AU - Bernengo, Maria Grazia

AU - Davidson, Neville

AU - Polders, Larissa

AU - Praet, Michel

AU - Spatz, Alan

PY - 2013

Y1 - 2013

N2 - The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.

AB - The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.

KW - Adjuvants, Immunologic

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cancer Vaccines

KW - Disease-Free Survival

KW - Female

KW - G(M2) Ganglioside

KW - Hemocyanin

KW - Humans

KW - Kaplan-Meier Estimate

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Neoplasm Staging

KW - Saponins

KW - Skin Neoplasms

KW - Watchful Waiting

U2 - 10.1200/JCO.2012.47.9303

DO - 10.1200/JCO.2012.47.9303

M3 - Journal article

VL - 31

SP - 3831

EP - 3837

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -